Get today's headlines by email
The investigation was prompted by public complaints and concerns from the FDA about improper use of a cosmetic brand. These products were allegedly mixed with saline solution and injected into clients at cosmetic clinics. The suspects reportedly produced glutathione-based products, which were marketed as skin-whitening treatments but incorrectly registered as cosmetics to avoid stringent drug regulations.
In their misleading marketing efforts, the items were sold as injectable treatments and falsely presented as imported products. Law enforcement coordinated with the FDA to investigate and identify multiple legal violations. Those involved are expected to face charges under laws governing cosmetics, medical devices, and pharmaceuticals, which include importing unlabeled cosmetics, false labeling, and selling unauthorized medical devices.
Supatra Boonserm, secretary-general of Thailand’s FDA, highlighted the misuse of the cosmetic registration process to bypass proper drug approval. She urged caution, emphasizing that injectable products are high-risk and require comprehensive safety assessments.
Central Investigation Bureau Commissioner Lt. Gen. Natsak Chewnasai underscored the dangers of injecting unapproved substances, citing risks such as infections and severe allergic reactions. Authorities aim to educate both providers and consumers about the importance of verifying product safety to prevent public harm.
Join the discussion?
Already a member?
Adapted by ASEAN Now · Khaosod · 20 May 2026
- 0 comments
- 248 views
-
snoop1130